Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 14,494 shares of Alimera Sciences stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total transaction of $17,827.62. Following the completion of the transaction, the insider now directly owns 98,619 shares in the company, valued at $121,301.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Alimera Sciences, Inc. (NASDAQ ALIM) traded up $0.02 during trading hours on Monday, hitting $1.11. 157,891 shares of the stock traded hands, compared to its average volume of 163,165. Alimera Sciences, Inc. has a 1-year low of $1.03 and a 1-year high of $1.72. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. The firm has a market capitalization of $76.75, a P/E ratio of -3.58 and a beta of 1.79.
A hedge fund recently raised its stake in Alimera Sciences stock. Stonepine Capital Management LLC lifted its stake in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 477,226 shares of the biopharmaceutical company’s stock after buying an additional 292,399 shares during the period. Alimera Sciences makes up approximately 0.4% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned 0.69% of Alimera Sciences worth $644,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 41.79% of the company’s stock.
ALIM has been the topic of several analyst reports. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Alimera Sciences in a report on Wednesday, November 22nd. Cowen reaffirmed a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Finally, ValuEngine downgraded shares of Alimera Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Alimera Sciences currently has a consensus rating of “Hold” and a consensus target price of $3.38.
WARNING: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/13/insider-selling-alimera-sciences-inc-alim-insider-sells-17827-62-in-stock.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.